The DOI matches its Crossref record.
Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply
Abstract
Thank you for forwarding the letter of the distinguished colleagues, Andre Scheen and Luc Van Gaal, and the opportunity to respond. The potential of rimonabant, the first representative of a new class of drugs, the CB1-receptor blocker, to induce weight loss and beneficial metabolic effects in support of a healthier lifestyle are undoubtedly impressive (references 3 and 4 of the letter). Guidelines, however, are to be based on available evidence in the form of published, full papers at the time they are consented. In view of this pre-condition, we regret that the rimonabant data in patients with diabetes were published after the complex work of the guideline-producing process had been terminated. Moreover, some of these data are still available in the abstract format only (reference 5 of the letter). When time comes to update the Joint ESC/EASD Guidelines on Diabetes, Prediabetes and Cardiovascular Diseases, we certainly foresee the need to consider also the state of affair in terms of rimonabant. By that time, it would be rather helpful if the weight-reducing and metabolic effects in high-risk patients with type 2 diabetes could be shown to indeed translate into a reduction of major cardiovascualar events or appropriate surrogate markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Piepoli, M. F., Corrà, U., Benzer, W., Bjarnason-Wehrens, B., Dendale, P., Gaita, D., McGee, H., Mendes, M., Niebauer, J., Zwisler, A.-D. O., et al. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283313592 · Cited by 796
Schramm, T. K., Gislason, G. H., Køber, L., Rasmussen, S., Rasmussen, J. N., Abildstrøm, S. Z., Hansen, M. L., Folke, F., Buch, P., Madsen, M., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.720847 · Cited by 538
What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review
Chimen, M., Kennedy, A., Nirantharakumar, K., Pang, T. T., Andrews, R., & Narendran, P. (2012) · Diabetologia · doi:10.1007/s00125-011-2403-2 · Cited by 438
Metadata
- Authors
- Ryden, L., & Standl, E.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-01
- Volume
- 28
- Issue
- 11
- Pages
- 1402-1402
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W4234314368
- Cited by
- 365
- References
- 0
- FWCI
- 29.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply. https://app.cochat.ai/papers/10.1093/eurheartj/ehm124
- The paper
- Ryden, L., & Standl, E. (2007). Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply. European Heart Journal. https://doi.org/10.1093/eurheartj/ehm124
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.